Recombinant human erythropoietin improves neurological outcomes in very preterm infants.

ABSTRACT:

Objective

To evaluate the efficacy and safety of repeated low-dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants.

Methods

A total of 800 infants of ≤32-week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n = 366) or placebo (n = 377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age.

Results

Death and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in th

SUBMITTER: Song J 

PROVIDER: S-EPMC5084793 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature